EGFR and non-small cell lung carcinoma: EGFR-mutated NSCLC has very limited response to current checkpoint inhibitors [2, 71] and so studies of the immune landscape in cancers with these driver mutations are crucial to understand mechanisms underlying the lack of response to immunotherapy.